An 8-Week Randomized, Double-Blind, Parallel-Group, Multi-Center, Active-Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension.

Trial Profile

An 8-Week Randomized, Double-Blind, Parallel-Group, Multi-Center, Active-Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2011

At a glance

  • Drugs Aliskiren/hydrochlorothiazide (Primary) ; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ACTION
  • Sponsors Novartis
  • Most Recent Events

    • 20 Jun 2011 Central blood pressure results presented at the 21st European Meeting on Hypertension.
    • 09 Jun 2011 Pooled pharmacodynamic results assessing the effects of treatment on plasma renin activity published in the Journal of Clinical Pharmacology.
    • 01 May 2010 Results presented at 25th Annual Scientific Meeting of the American Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top